A share price of Viridian Therapeutics Inc [VRDN] is currently trading at $19.43, down -0.97%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The VRDN shares have gain 2.97% over the last week, with a monthly amount glided 7.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wells Fargo downgraded its rating to Equal Weight on December 19, 2024, and dropped its price target to $27. On November 25, 2024, TD Cowen initiated with a Buy rating. Needham reiterated its Buy rating and increased its price target to $38 on September 11, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $29 as its price target on June 11, 2024. Goldman started tracking with a Buy rating for this stock on June 06, 2024, and assigned it a price target of $23. In a note dated May 09, 2024, Ladenburg Thalmann downgraded a Neutral rating on this stock.
Viridian Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $9.90 and $27.20. Currently, Wall Street analysts expect the stock to reach $22.79 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $19.43 at the most recent close of the market. An investor can expect a potential return of 17.29% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Trailing Twelve Months sales for Viridian Therapeutics Inc [NASDAQ:VRDN] were 0.30M which represents 4.17% growth. Gross Profit Margin for this corporation currently stands at 0.6% with Operating Profit Margin at -1218.31%, Pretax Profit Margin comes in at -1128.07%, and Net Profit Margin reading is -1128.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.55 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Viridian Therapeutics Inc [NASDAQ:VRDN] is 11.01. In addition, the Quick Ratio stands at 11.01 and the Cash Ratio stands at 2.23. Considering the valuation of this stock, the price to sales ratio is 5289.00, the price to book ratio is 4.86.
Transactions by insiders
Recent insider trading involved Beetham Thomas W., Chief Operating Officer, that happened on Sep 27 ’24 when 5000.0 shares were purchased. President and CEO, Mahoney Stephen F. completed a deal on Sep 27 ’24 to buy 21400.0 shares.